10-Q: HeartSciences Boosts Capital, Advances AI-ECG Amidst Losses

HeartSciences Inc. reports increased cash and equity from recent capital raises, advancing its AI-ECG technology and FDA submissions despite ongoing net losses and going concern doubts.

Summary

• HeartSciences Inc. reported a net loss of $2.1 million for the three months ended July 31, 2025, a slight increase from $2.05 million in the same period of 2024.
• Cash and cash equivalents significantly increased to $2.79 million as of July 31, 2025, up from $1.10 million on April 30, 2025.
• Total stockholders' equity rose substantially to $3.14 million as of July 31, 2025, from $0.21 million on April 30, 2025.
• The company raised approximately $4.6 million in gross proceeds from the Series D Preferred Stock and warrants offering during the quarter, with an additional $0.8 million raised subsequent to July 31, 2025.
• Debt principal of $1.02 million was exchanged for 274,159 shares of Common Stock with Streeterville during the quarter, and an additional $0.7 million principal for 205,237 shares post-quarter.
• Research and development expenses decreased by 19% to $997,206 for the quarter, primarily due to reduced cloud consulting costs.
• Interest expense surged by 715% to $183,688 for the quarter, mainly due to the Streeterville Note.
• The company received FDA Breakthrough Device designation in June 2025 for its aortic stenosis ECG algorithm.
• A foundational patent was granted by the USPTO in June 2025 for estimating echocardiography parameters using an ECG.
• Management identified material weaknesses in internal control over financial reporting, including lack of proper approval processes, insufficient US GAAP/SEC accounting resources, and inadequate staff for segregation of duties.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to significant capital raises improving liquidity and equity, key regulatory and intellectual property milestones (FDA Breakthrough, patent), and strategic collaborations. However, persistent net losses, ongoing 'going concern' doubts, and identified internal control weaknesses temper the overall outlook, indicating continued high risk.

Positives

• Cash and cash equivalents increased significantly to $2.79 million, providing improved liquidity.
• Total stockholders' equity rose substantially to $3.14 million, addressing Nasdaq's minimum equity requirement.
• Secured FDA Breakthrough Device designation for its aortic stenosis ECG algorithm, potentially accelerating regulatory review.
• Granted a foundational patent by the USPTO for estimating echocardiography parameters using an ECG, strengthening intellectual property.
• Reduced research and development expenses by 19% to $997,206, indicating cost management in product development.
• Launched Phase 1 of the MyoVista Insights Cloud Platform, establishing a foundation for future recurring subscription revenues.
• Strategic collaborations with Mount Sinai and Rutgers are expected to accelerate product development and expand AI-ECG algorithms.

Negatives

• The company continues to incur net losses, with a net loss of $2.05 million for the quarter.
• Substantial doubt exists regarding the company's ability to continue as a going concern due to recurring losses and negative cash flows.
• Interest expense increased by 715% to $183,688, reflecting higher debt servicing costs.
• Identified material weaknesses in internal control over financial reporting, which could impact financial reporting reliability.
• Revenue remains minimal at $1,900 for the quarter, indicating the company is still in early commercialization stages.
• The company's public float is below $75 million, limiting its ability to sell shares under the ATM Facility to one-third of its aggregate market value.

Risks

• Inability to receive regulatory clearance for MyoVista wav ECG or MyoVista Insights Cloud Platform and associated AI-ECG algorithms from the FDA or other foreign regulatory agencies.
• Failure to obtain additional capital through equity sales, debt, or strategic partnerships, which is necessary to fund operations to achieve commercialization.
• Potential for further material write-downs of inventory due to obsolescence if FDA clearance and/or market acceptance of the MyoVista wav ECG are not achieved.
• Failure to maintain Nasdaq continued listing requirements, which could result in de-listing and penny stock trading.
• Impact of competition and new technologies in the medical device industry.
• Potential litigation that could have a material adverse effect on financial position, operating results, or cash flows.
• Material weaknesses in internal control over financial reporting could adversely affect the ability to record, process, summarize, and report financial information.

Future Outlook

The company expects to continue investing significantly in R&D, clinical studies, and go-to-market strategies. It plans to make separate FDA submissions for the MyoVista wav ECG device (expected in calendar 2025) and its first self-developed AI-ECG algorithm for low-ejection fraction on the MyoVista Insights Cloud Platform (aiming for H1 calendar 2026). Revenues are anticipated from install fees and SaaS-based usage fees for the cloud platform and device-based consumable revenue. The company believes its current resources are insufficient to fund operations to achieve commercialization and will need to raise additional capital.

Management Comments

• Management believes that current resources would be insufficient to fund operations to achieve commercialization.
• Management's plans include raising capital through the sale of additional equity securities, debt, or capital inflows from strategic partnerships.
• Management can provide no assurance that such financing or strategic relationships will be available on acceptable terms, or at all, which would likely have a material adverse effect on the Company and its financial statements.
• We believe that there is currently no low-cost, front-line, medical device that is effective at screening broadly for many types of heart disease.
• We believe that adding the capability to detect a broader range of cardiac conditions to the standard 12-lead resting ECG could help improve cardiac referral pathways and be valuable for patients, physicians, health systems and third-party payors.

Industry Context

HeartSciences operates in the rapidly evolving medical technology sector, specifically focusing on AI-enhanced electrocardiography (ECG) for cardiovascular diagnostics. The industry is seeing a trend towards integrating AI into traditional diagnostic tools to improve accuracy, expand clinical utility, and enable earlier detection of conditions like cardiac dysfunction, which traditionally required more expensive imaging. The company's strategy to offer both a proprietary device (MyoVista wav ECG) and a device-agnostic cloud platform (MyoVista Insights Cloud Platform) aligns with the broader industry push for flexible, scalable, and accessible diagnostic solutions. The FDA's recent De Novo clearance for cardiovascular machine learning-based notification software and subsequent 510(k) clearances for AI algorithms (like for low ejection fraction) indicate a growing regulatory pathway and market acceptance for AI in cardiology, which is favorable for HeartSciences.

Comparison to Industry Standards

• The company's focus on expanding ECG's clinical utility to detect a broader range of cardiac indications, including structural and ischemic disease, addresses a recognized limitation of conventional resting ECGs, which have limited sensitivity in these areas. This aligns with the industry's need for more effective frontline screening tools, as highlighted by the 2012 U.S. Preventive Services Task Force evaluation on conventional ECG testing.
• The FDA's grant of an industry-first De Novo clearance in August 2023 for a new Class II product code for cardiovascular machine learning-based notification software (e.g., for hypertrophic cardiomyopathy) and subsequent 510(k) clearance for a low ejection fraction algorithm set a precedent that HeartSciences is leveraging for its own submissions. This indicates the company is pursuing established, albeit new, regulatory pathways for AI-ECG algorithms, similar to other innovators in the space.
• The collaboration with Mount Sinai for commercializing AI cardiovascular algorithms positions HeartSciences alongside leading academic medical centers that are at the forefront of AI development in healthcare, similar to how other med-tech companies partner with research institutions to validate and commercialize novel technologies.
• The company's strategy to update its impaired cardiac relaxation algorithm to new American Society of Echocardiography (ASE) published age-based measures prior to FDA submission demonstrates adherence to evolving clinical guidelines, a critical aspect for medical device companies seeking regulatory approval and market acceptance.

Corporate Governance

Legal Proceedings

• No material claims outstanding or pending against the company as of July 31, 2025.

Related Party Transactions

• The FRV Note of $500,000 was issued to Front Range Ventures LLC (FRV), a shareholder of the company at the time of issuance. The maturity date was extended to September 30, 2025.
• Royalty payments are due to the company's founder, Guangren Gary Chen, based on MyoVista wav ECG device unit sales, with a first priority security interest and pledge on the covered technology.

Stakeholder Impact

• **Shareholders**: Experience dilution from ongoing equity raises (Series D Preferred Stock, ATM Facility, Equity Line) but benefit from improved liquidity and increased stockholders' equity, which helps maintain Nasdaq listing. Positive impact from FDA Breakthrough Device designation and patent grant, potentially increasing long-term value. However, continued net losses and going concern doubts remain a concern.
• **Employees**: Benefit from stock-based compensation grants (stock options, RSUs) under the Equity Incentive Plan, aligning their interests with company performance. The company's continued operations and R&D efforts provide job security and opportunities.
• **Customers/Patients**: Potential for improved cardiac screening tools with the MyoVista wav ECG and MyoVista Insights Cloud Platform, offering earlier detection of heart disease. FDA clearances are critical for product availability.
• **Creditors**: Debt-to-equity conversions (e.g., with Streeterville) reduce outstanding debt principal, improving the company's debt profile. However, the 'going concern' warning indicates elevated risk for remaining debt holders.
• **Regulatory Authorities**: The company is actively engaging with the FDA for product clearances and has received Breakthrough Device designation, demonstrating compliance and innovation within regulatory frameworks.

Next Steps

• Submit the MyoVista wav ECG device for FDA clearance in calendar 2025.
• Update the impaired cardiac relaxation algorithm to new ASE published age-based measures prior to FDA submission.
• Aim for FDA submission of a low-ejection fraction algorithm for the MyoVista Insights Cloud Platform during the first half of calendar 2026.
• Continue efforts to raise additional capital through equity, debt, or strategic partnerships.
• Implement remedial steps to improve internal controls over financial reporting.
• Seek shareholder approval for the amendment to the 2023 Equity Incentive Plan to increase the maximum aggregate number of shares to 1,000,000 at the 2025 Annual Meeting of Shareholders.
• Regain compliance with Nasdaq's minimum stockholders' equity requirement by September 15, 2025.

Key Dates

Recommendation

HeartSciences Inc. is in a critical pre-commercialization phase, marked by significant R&D investment and reliance on regulatory approvals. While the company has made notable progress, including securing FDA Breakthrough Device designation, obtaining a foundational patent, and successfully raising capital to bolster its liquidity and stockholders' equity (addressing Nasdaq compliance), it continues to operate at a net loss and faces substantial doubt about its ability to continue as a going concern. The increased cash position and reduced debt are positive, but the company's future success hinges entirely on obtaining FDA clearances and achieving market acceptance for its products. For a seasoned investor, the stock remains highly speculative. A 'hold' recommendation is appropriate for existing investors to monitor the progress of FDA submissions and commercialization efforts, given the recent positive developments. However, new investors should approach with extreme caution due to the inherent risks of an early-stage medical technology company with a history of losses and ongoing funding needs.

Keywords

AI-ECG, Cardiovascular Diagnostics, Medical Technology, FDA Clearance, MyoVista wav ECG, MyoVista Insights Cloud Platform, Heart Disease Screening, Cardiac Dysfunction, Biotechnology, Healthcare Technology